X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
AB1010 (masitinib) is a tyrosine kinase inhibitor, small molecule drug. It is being evaluated in phase 3 clinical studies in combination with Rilutek (riluzole) for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2024
Details:
AB1010 (masitinib), is one of the most promising drugs in ALS that has just been submitted to the EMA conditional approval process. Masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
AB1010 (masitinib), is one of the most promising drugs in ALS that has just been submitted to the EMA conditional approval process. Masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
AB1010 (masitinib) is a tyrosine kinase inhibitor, emphasizes the neuro-inflammatory activity of ALS by targeting macrophages, mast cells, and microglia cells. It downregulates the proinflammatory cytokines, indirectly reduces inflammation, and induces neuroprotection.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
The proceeds will be used to fund the development of AB1010 (masitinib) for the treatment of amyotrophic lateral sclerosis and the development of the microtubule destabilizer agents (MDA) platform, with the clinical development of AB8939 in refractory acute myeloid leukemia.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 24, 2023
Details:
AB1010 (masitinib), a tyrosine kinase inhibitor, emphasizes the neuro-inflammatory activity of ALS by targeting macrophages, mast cells, and microglia cells. It downregulates the proinflammatory cytokines, indirectly reduces inflammation, and induces neuroprotection.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
AB1010 (masitinib), is one of the most promising drugs in ALS that has just been submitted to the EMA conditional approval process. Masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
AB1010 (masitinib), targets microglia and mast cells, which are two cells of the innate immune system associated with the pathology of progressive MS. The mechanism of action of masitinib is different from and potentially complementary to other tyrosine kinase inhibitors.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2022
Details:
AB1010 (masitinib) is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity. It can be developed for number of conditions in oncology, inflammatory diseases, and in CNS diseases.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
AB1010 (masitinib) is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity. In vivo, masitinib blocked tumour growth in mice with subcutaneous grafts of Ba/F3 cells.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Masitinib (AB1010) is an oral tyrosine kinase inhibitor that has demonstrated neuroprotective action in neurodegenerative diseases via inhibition of mast cell and microglia/macrophage activity.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
Masitinib (AB1010) is an oral tyrosine kinase inhibitor that has demonstrated neuroprotective action in neurodegenerative diseases via inhibition of mast cell and microglia/macrophage activity.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
The study demonstrated ability of masitinib to specifically inhibit another essential enzyme responsible for replication of virus: 3CLpro, the main protease of SARS-CoV-2. To date, masitinib is the only antiviral treatment in the world that specifically targets this protein.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
Long-term follow-up survival data showing a significant benefit in favor of Alsitek (masitinib) in moderate ALS patients (between group difference in median OS of +25 months, hazard ratio 0.56 (95%CI [0.32;0.96])).
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: Alsitek
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
Phase 3 study evaluating AB1010, oral masitinib at 6 mg/kg/d versus placebo in severe asthma uncontrolled by oral corticosteroids met its primary endpoint. Masitinib decreased the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by OCS.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
The authorization was made based on a pre-submission package sent by AB Science including efficacy data of study AB10015, long-term survival data (75 months average follow-up from diagnosis) of study AB10015, and safety data.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Study demonstrated ability of masitinib to specifically inhibit another essential enzyme responsible for replication of virus: 3CLpro, main protease of SARS-CoV-2. To date, masitinib is the only antiviral treatment in world that specifically targets this protein.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
AB1010 (masitinib), a selective tyrosine kinase inhibitor, modulates the activity of mast cells and macrophages in patients for the treatment of ALS, and is currently developed in three therapeutic areas: neurology, inflammatory diseases and oncology.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Details:
Study AB10015 previously showed that masitinib (4.5 mg/kg/day) as an add-on to standard riluzole, significantly slowed functional decline at week 48 relative to those treated with riluzole alone.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2022
Details:
AB20006 (masitinib), potent inhibitor of mast cell activation received authorization to initiate Phase II study, on the basis of its ability to substantially reduced severe mast cell mediator release symptoms in treatment of patients with severe mast cell activation syndrome.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Oncology Product Name: AB20006
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
Company initiated Phase III study on the basis of results from Phase 2B/3 study of AB1010 (Masitinib) which showed significant reduction in the risk of first disability progression by 42% and the risk of confirmed disability progression by 37%.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2022
Details:
Masitinib is a orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2021
Details:
Masitinib is orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity through inhibiting limited number of kinases, can be developed in oncology, inflammatory diseases, and certain diseases of central nervous system.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Oncology Product Name: AB20006
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
Masitinib is being developed as a novel SARS-CoV-2 protease inhibitor antiviral therapy in non-hospitalized (non-severe) and hospitalized (severe) COVID-19 patients. Masitinib is a orally administered tyrosine kinase inhibitor that targets mast cells and macrophages.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB20001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
Masitinib is being developed as a novel SARS-CoV-2 protease inhibitor antiviral therapy, with two phase 2 studies in the complementary populations of non-hospitalized (non-severe) and hospitalized (severe) COVID19 patients.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
Study AB09004 was the first successful phase 3 randomized trial in mild-to-moderate Alzheimer’s disease of a drug targeting innate immune cells of the neuroimmune system. Masitinib at 4.5 mg/kg/day showed significant benefit over placebo according to the primary analysis.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2021
Details:
Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Immunology Product Name: AB15003
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
AB Science has decided to suspend inclusion in ongoing studies with masitinib until the investigation of this potential safety issue is finished. AB Science is working closely with the ANSM and other regulatory agencies to complete the necessary additional analyses.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Immunology Product Name: AB15003
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
Details:
Masitinib is a tyrosine kinase inhibitor designed to selectively target mast cells (MCs) and macrophages. Masitinib in combination with docetaxel as first-line treatment of metastatic Castrate Refractory Prostate Cancer (mCRPC) eligible to chemotherapy.
Lead Product(s): Masitinib Mesylate,Docetaxel,Prednisone
Therapeutic Area: Oncology Product Name: AB12003
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
Details:
This collaboration follows the discovery by the University of Chicago that masitinib inhibits the main protease (3CLpro) necessary for the SARS-CoV-2 viral replication cycle.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB20001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Chicago
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 06, 2021
Details:
Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Final results of study AB12003 will be available in April 2021.
Lead Product(s): Masitinib Mesylate,Docetaxel,Prednisone
Therapeutic Area: Oncology Product Name: AB12003
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Details:
This agreement will enable AB Science to fund the clinical development programme evaluating masitinib as a treatment for COVID-19.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 30, 2020
Details:
The pre-specified primary analysis was rate of severe asthma exacerbations, with masitinib demonstrating a statistically significant 29% reduction in severe exacerbations relative to placebo.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Masitinib selectively targets mast cells through inhibition of tyrosine kinases c-Kit, LYN and FYN. Phase 3 study (AB07105) evaluating oral masitinib at 6 mg/kg/day versus placebo in severe asthma uncontrolled by oral corticosteroids (OCS) met its primary endpoint.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Masitinib, AB Science's lead product, is an oral tyrosine kinase inhibitor that specifically targets innate immunity of MS patients. Masitinib at a dose of 4.5 mg/kg/day slowed disease progression in patients, which was the study’s primary objective.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
Masitinib is a first in class oral drug in severe asthma, selectively targeting mast cells through inhibition of tyrosine kinases c-Kit, LYN and FYN.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
Starting from a library of 1,900 clinically used drugs, either approved for human use or in late stage clinical development, masitinib stood-out in its ability to completely inhibit activity of the SARS-CoV-2 main protease (3CLpro), thereby blocking viral replication.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
The current research provides evidence suggesting that masitinib’s therapeutic efficacy is associated with a synapto-protective action in relation with mast cells inhibition.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
The European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted AB Science phase 3 study AB07015 results with masitinib in severe asthma.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
Study AB19001 is an international Phase 3 study to compare the efficacy and safety of masitinib in combination with riluzole vs placebo in combination with riluzole in ALS.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
Details:
Masitinib significantly delays disability progression on EDSS in patients with primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2020
Details:
Study AB12003 is a multicenter, randomized, double blind, placebo-controlled, 2-parallel group, Phase 3 study in metastatic castrate resistant prostate cancer eligible to chemotherapy.
Lead Product(s): Masitinib Mesylate,Docetaxel,Prednisone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
